Christine M. Slover, PharmD

Shionogi Inc.

Disclosure(s): Shionogi: Employee

Poster(s):

• 1711 - In Vitro Activity of Cefiderocol Against US Achromobacter spp. and Burkholderia spp. Clinical Isolates from the SENTRY Surveillance Program 2020-2021
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1715 - In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1734 - Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET